In one trial, the condition occurred in 4% of those on Wegovy who had type 2 diabetes and overweight compared to 2.7% of the placebo group
K., Liu, B., Cui, X., & Brown, K., for the SURPASS-2 Investigators
Weight loss results In a 2022 review of 22 studies that included more than 17,000 people with or without type 2 diabetes treated with semaglutide or liraglutide: More than 50% of participants treated with either semaglutide or liraglutide lost 5% or more of their starting weight after an average of 39 weeks on the medicine About 17% of participants lost 10% or more of their body weight in the same period A phase 3 clinical trial studied treatment with tirzepatide in people with obesity and found that it produced substantial and sustained weight loss at various dose strengths
It is frequently used as a gentler entry point for GH secretagogue therapy or as a stand-alone protocol for patients seeking sleep quality and recovery improvement with a well-characterized safety profile
Food interactions Information not available
In the current study a course of triple drug regimen consisting of nizatidine (300mg once daily for 6 weeks), clarithromycin (500 mg twice daily for 10 days) and amoxicillin (1000mg twice daily for 10 days) was used to eradicate H.pylori